Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03426761 · ClinicalTrials.gov registry record · Phase 4
Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections
A Phase 4 study of Prosthetic-joint Infection and Joint Infection, sponsored by Infectious Diseases Physicians.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT03426761 is a Phase 4 study of Prosthetic-joint Infection and Joint Infection that has completed, run by Infectious Diseases Physicians. The registered enrollment target is 41 participants, below the 94-participant average among 9 other Prosthetic-joint Infection trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03426761, a Phase 4 study of Prosthetic-joint Infection and Joint Infection, has completed, sponsored by Infectious Diseases Physicians.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
Because of its prolonged terminal half-life, dalbavancin is an extremely attractive option in treating Gram-positive infections caused by S. aureus including MRSA, and streptococcal species. Systemic bacterial infections due to Staphylococci such as osteomyelitis and septic arthritis, are conditions which require prolonged IV therapy, typically for at least 3-6 weeks, though sometimes more. Due to dalbavancin's prolonged terminal half-life, it may offer the opportunity to substantially reduce costs and morbidity in native joint and prosthetic joint infections with one infusion every fourteen days until completion of therapy.
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG Dalbavancin
Study Locations (1)
Virginia
- Infectious Diseases Physicians, Inc. - Annandale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-01-25 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03426761
The ClinicalTrials.gov registry entry for NCT03426761 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 9 other Prosthetic-joint Infection trials with a reported enrollment target (56% lower). The listed sponsor is Infectious Diseases Physicians, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Prosthetic-joint Infection appearing as the primary indexed condition, and to 2 interventions - of which Vancomycin is the first listed.
NCT03426761 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT03426761 about?
NCT03426761 is a clinical study titled "Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections". Because of its prolonged terminal half-life, dalbavancin is an extremely attractive option in treating Gram-positive infections caused by S. aureus including MRSA, and streptococcal species. Systemic bacterial infections due to Staphylococci such as osteomyelitis and septic arthritis, are conditions...
What is the current status of trial NCT03426761?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2018-01-25. Estimated completion is 2022-12-31.
What conditions does trial NCT03426761 study?
This clinical trial studies the following conditions: Prosthetic-joint Infection, Joint Infection, Septic Arthritis, Osteomyelitis, Bone Infection.
What interventions are being tested in trial NCT03426761?
The interventions under investigation include: Vancomycin (DRUG), Dalbavancin (DRUG).
Who is sponsoring clinical trial NCT03426761?
This trial is sponsored by Infectious Diseases Physicians, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03426761 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prosthetic-joint Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty
COMPLETED · Phase 4
-
The Effect of Peri-Operative Adjunctive Probiotics on Immunological Markers in Cases of Prosthetic Joint Infection of the Hip and Knee
RECRUITING · NA
-
Real-component Vs All-cement Articulating Spacers for Periprosthetic Knee Infection
RECRUITING · NA
-
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
RECRUITING · Phase 2
-
Reduction of Bacterial Seeding in Total Shoulder Arthroplasty
RECRUITING · NA
-
A Second Trial of the Abbreviated Protocol Two-Stage Exchange
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.